Archive

« Older Entries

LSP portfolio company Simplify Medical receives FDA Approval Monday, September 21st, 2020
...for 1-Level Simplify Disc PMA   Simplify Disc overall success rate of 93.0% was superior to the ACDF control   SUNNYVALE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Simplify Medical, a privately- [...]
LSP portfolio company Immunic announced very positive phase II top-line data Friday, August 14th, 2020
in multiple sclerosis and subsequently raised $ 103.5 million in a public offering     Munich / Amsterdam, August 14, 2020. Immunic, a Munich and New York based company founded, seed- and growth-funded b [...]
LSP portfolio company Lumeon raises $ 30 million Wednesday, August 12th, 2020
Amsterdam, 12 August 2020. Lumeon, the leader in care pathway orchestration, successfully raised USD 30 million in a series D financing. The investment will be used to support U.S. growth, expand its care delivery pla [...]
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A Wednesday, July 29th, 2020
financing round to advance therapies for rare central nervous system diseases   AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease [...]
LSP portfolio company DNA Script closes oversubscribed expansion of the B round Wednesday, July 29th, 2020
PARIS and SOUTH SAN FRANCISCO, Calif., July 29, 2020—DNA Script today announced a $50 million extension to its Series B financing, bringing the total investment of this round to $89 million. This oversubscribed roun [...]
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer Tuesday, July 28th, 2020
Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer   UTRECHT, The Netherlands and CAMBRI [...]
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer Tuesday, July 28th, 2020
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® an [...]
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina Tuesday, July 21st, 2020
  Novel gene therapy designed to stimulate formation of new coronary blood vessels is being studied in patients with treatment-resistant angina with no remaining treatment options   July 21, 2020 07:00 A [...]
LSP invests in EUR 32 million Series B financing of VarmX Wednesday, July 8th, 2020
VarmX develops innovative reversal agents for the treatment and prevention of severe bleeding in patients on oral anticoagulants Proceeds will be used to achieve clinical proof of concept for lead compound, [...]
Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties Wednesday, July 8th, 2020
Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with multiple myelo [...]

« Older Entries

2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

Archive

« Older Entries

LSP portfolio company Simplify Medical receives FDA Approval Monday, September 21st, 2020
...for 1-Level Simplify Disc PMA   Simplify Disc overall success rate of 93.0% was superior to the ACDF control   SUNNYVALE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Simplify Medical, a privately- [...]
LSP portfolio company Immunic announced very positive phase II top-line data Friday, August 14th, 2020
in multiple sclerosis and subsequently raised $ 103.5 million in a public offering     Munich / Amsterdam, August 14, 2020. Immunic, a Munich and New York based company founded, seed- and growth-funded b [...]
LSP portfolio company Lumeon raises $ 30 million Wednesday, August 12th, 2020
Amsterdam, 12 August 2020. Lumeon, the leader in care pathway orchestration, successfully raised USD 30 million in a series D financing. The investment will be used to support U.S. growth, expand its care delivery pla [...]
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A Wednesday, July 29th, 2020
financing round to advance therapies for rare central nervous system diseases   AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease [...]
LSP portfolio company DNA Script closes oversubscribed expansion of the B round Wednesday, July 29th, 2020
PARIS and SOUTH SAN FRANCISCO, Calif., July 29, 2020—DNA Script today announced a $50 million extension to its Series B financing, bringing the total investment of this round to $89 million. This oversubscribed roun [...]
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer Tuesday, July 28th, 2020
Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer   UTRECHT, The Netherlands and CAMBRI [...]
Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer Tuesday, July 28th, 2020
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® an [...]
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina Tuesday, July 21st, 2020
  Novel gene therapy designed to stimulate formation of new coronary blood vessels is being studied in patients with treatment-resistant angina with no remaining treatment options   July 21, 2020 07:00 A [...]
LSP invests in EUR 32 million Series B financing of VarmX Wednesday, July 8th, 2020
VarmX develops innovative reversal agents for the treatment and prevention of severe bleeding in patients on oral anticoagulants Proceeds will be used to achieve clinical proof of concept for lead compound, [...]
Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties Wednesday, July 8th, 2020
Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with multiple myelo [...]

« Older Entries

2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview